Drugs for Roussy-Levy Hereditary Areflexic Dystasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 32)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
ácido fólico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
|
Folipac
Folsaeure
Folsan
Folsaure
Folsäure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-Pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-pteroyl-L-glutamic acid
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
2 |
|
Trace Elements |
|
Phase 4 |
|
|
|
3 |
|
Vitamins |
|
Phase 4 |
|
|
|
4 |
|
Nutrients |
|
Phase 4 |
|
|
|
5 |
|
Micronutrients |
|
Phase 4 |
|
|
|
6 |
|
Antioxidants |
|
Phase 4 |
|
|
|
7 |
|
Protective Agents |
|
Phase 4 |
|
|
|
8 |
|
Alpha-lipoic Acid |
|
Phase 4 |
|
|
|
9 |
|
Vitamin B Complex |
|
Phase 4 |
|
|
|
10 |
|
Folate |
|
Phase 4 |
|
|
|
11 |
|
Thioctic Acid |
|
Phase 4 |
|
|
|
12 |
|
Vitamin B9 |
|
Phase 4 |
|
|
|
13 |
|
Acetylcarnitine |
Approved, Investigational |
Phase 2, Phase 3 |
|
3040-38-8 |
7045767 |
Synonyms:
(-)-Acetylcarnitine
(+-)-Acetylcarnitine
(R)-Acetylcarnitine
3-(Acetyloxy)-4-(trimethylammonio)butanoate
3-(Acetyloxy)-4-(trimethylammonio)butanoic acid
Acetyl carnitine
Acetyl L carnitine
Acetylcarnitine
Acetyl-carnitine
Acetylcarnitine, (R)-isomer
Acetyl-DL-carnitine
Acetyl-L-(-)-carnitine
acetyl-L-carnitine
Acetyl-L-carnitine
ALC
|
Alcar
Branigen
Carnitine, acetyl
DL-O-Acetylcarnitine
L-Acetylcarnitine
L-Carnitine acetyl ester
Levocarnitine acetyl
L-O-Acetylcarnitine
Medosan
Nicetile
O-Acetyl-(R)-carnitine
O-Acetylcarnitine
O-acetyl-L-carnitine
O-Acetyl-L-carnitine
R-Acetylcarnitine
|
|
14 |
|
Naltrexone |
Approved, Investigational, Vet_approved |
Phase 3 |
|
16590-41-3 |
5360515 |
Synonyms:
16590-41-3
16676-29-2
17-(Cyclopropylmethyl)-4,5a-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
3,14-dihydroxy-17-(cyclopropylmethyl)-4,5alpha-epoxymorphinan-6-one
Antaxone
BIDD:GT0405
BPBio1_000146
BRD-K88172511-310-03-8
Bristol myers squibb brand OF naltrexone hydrochloride
Bristol-myers squibb brand OF naltrexone hydrochloride
BRN 3596648
BSPBio_000132
C07253
CCRIS 3506
Celupan
CHEBI:121459
CHEBI:7465
CHEMBL142
CID5360515
D05113
DB00704
Depade
Du pont brand OF naltrexone hydrochloride
EINECS 240-649-9
EN-1639A
HMS2089O11
HS-0002
HSDB 6750
Hydrochloride, naltrexone
Lacer brand OF naltrexone hydrochloride
lamepro Brand OF naltrexone hydrochloride
LS-92094
MLS002153483
MolPort-004-920-221
MorViva
|
Nalorex
Naltrexon
Naltrexona
Naltrexona [INN-Spanish]
naltrexone
Naltrexone
naltrexone (ReVia)
Naltrexone (USAN/INN)
Naltrexone [Usan:Ban:Inn]
Naltrexone [USAN:BAN:INN]
Naltrexone [USAN:INN:BAN]
Naltrexone Hcl
Naltrexone hydrochloride
Naltrexonum
Naltrexonum [INN-Latin]
N-Cyclopropylmethyl-14-hydroxydihydromorphinone
N-Cyclopropylmethylnoroxymorphone
Nemexin
Orphan brand OF naltrexone hydrochloride
PDSP2_000847
Pharmazam brand OF naltrexone hydrochloride
Prestwick0_000116
Prestwick1_000116
Prestwick2_000116
Prestwick3_000116
PTI-555
ReVia
Schering plough brand OF naltrexone hydrochloride
Schering-plough brand OF naltrexone hydrochloride
SMP1_000206
SPBio_002071
Trexan
UM-792
UNII-5S6W795CQM
United drug brand OF naltrexone hydrochloride
Vivitrex
Vivitrol
Vivitrol (TN)
|
|
15 |
|
Sorbitol |
Approved |
Phase 3 |
|
50-70-4 |
5780 |
Synonyms:
(−)-sorbitol
(-)-Sorbitol
(2R,3R,4R,5S)-Hexane-1,2,3,4,5,6-hexol
Baxter brand OF sorbitol
D-(−)-sorbitol
D-(-)-Sorbitol
D-glucitol
D-Glucitol
Diakarmon
D-Sorbit
D-Sorbitol
D-SORBITOL
D-Sorbol
e 420
e420
e-420
Esasorb
Foodol D 70
GLC-Ol
Glucarine
Glucitol
g-Ol
G-ol
Karion
Karion instant
Klysma sorbit
Kyowa powder 50m
L-Gulitol
Medefield brand OF sorbitol
Medevac
Multitol
Neosorb
Neosorb 20/60dC
Neosorb 70/02
Neosorb 70/70
Neosorb P 20/60
Neosorb P 60
Neosorb P 60W
Nivitin
Pfizer brand OF sorbitol
|
Resulax
Sionit
Sionit K
Sionite
Sionon
Siosan
Sorbex m
Sorbex R
Sorbex RP
Sorbex S
Sorbex X
Sorbilande
Sorbilax
Sorbit
Sorbit D 70
Sorbit DP
Sorbit DP 50
Sorbit D-powder
Sorbit kyowa powder 50m
Sorbit L 70
Sorbit S
Sorbit T 70
Sorbit W 70
Sorbit WP
Sorbit W-powder
Sorbit W-powder 50
Sorbite
Sorbitol F
Sorbitol FK
Sorbitol FP
Sorbitol pfizer brand
Sorbitol S
Sorbitol syrup C
Sorbitur
Sorbo
Sorbogem 712
Sorbol
Sorbostyl
Trommsdorff brand OF sorbitol
Yal
|
|
16 |
|
Baclofen |
Approved |
Phase 3 |
|
1134-47-0 |
2284 |
Synonyms:
( inverted question mark)-Baclofen
(?)-Baclofen
(+-)-Baclofen
(+/-)- beta-(Aminoethyl)-4- chlorobenzenepropanoic acid
(+/-)-BACLOFEN
(+/-)-beta-(Aminomethyl)-4-chlorobenzenepropanoic acid
1134-47-0
4-Amino-3-(4-chlorophenyl)butanoic acid
4-amino-3-(4-Chlorophenyl)butyrate
4-amino-3-(4-Chlorophenyl)butyric acid
4-Amino-3-(4-chlorophenyl)butyric acid
62594-36-9
AB00051921
AC1L1DC6
AC-4530
Alphapharm brand OF baclofen
Alphapharm Brand of Baclofen
apo Baclofen
Apo Baclofen
apo-Baclofen
ApoBaclofen
Apo-Baclofen
Apotex brand OF baclofen
Apotex Brand of Baclofen
Ashbourne brand OF baclofen
Ashbourne Brand of Baclofen
ASTA medica brand OF baclofen
ASTA Medica Brand of Baclofen
Athena brand OF baclofen
Athena Brand of Baclofen
Atrofen
AWD, baclofen
AWD, Baclofen
B 5399
b-(4-Chlorophenyl)gaba
b-(Aminomethyl)-4-chlorobenzenepropanoate
b-(Aminomethyl)-4-chlorobenzenepropanoic acid
b-(Aminomethyl)-P-chlorohydrocinnamate
b-(Aminomethyl)-P-chlorohydrocinnamic acid
b-(P-Chlorophenyl)-g-aminobutyrate
b-(P-Chlorophenyl)-g-aminobutyric acid
B3343
B5399_SIGMA
Ba 34647
Ba34,647
Ba-34,647
Ba34647
Ba-34647
baclofen
Baclofen
Baclofen (JP15/USP/INN)
Baclofen (R,S)
Baclofen [USAN:INN:BAN:JAN]
Baclofen alphapharm brand
Baclofen Alphapharm Brand
Baclofen apotex brand
Baclofen Apotex Brand
Baclofen ashbourne brand
Baclofen Ashbourne Brand
Baclofen athena brand
Baclofen Athena Brand
Baclofen awd
Baclofen AWD
Baclofen ciba-geigy brand
Baclofen Ciba-Geigy Brand
Baclofen irex brand
Baclofen Irex Brand
Baclofen isis brand
Baclofen Isis Brand
Baclofen medtronic brand
Baclofen Medtronic Brand
Baclofen novartis brand
Baclofen Novartis Brand
Baclofen nu-pharm brand
Baclofen Nu-Pharm Brand
Baclofen pharmascience brand
Baclofen Pharmascience Brand
Baclofene
Baclofène
Baclofene [INN-French]
Baclofene Irex
Baclofène irex
BaclofeneIrex
Baclofene-Irex
Baclofène-irex
BaclofèneIrex
Baclofeno
Baclofeno [INN-Spanish]
Baclofenum
Baclofenum [INN-Latin]
Baclon
Baclophen
Baclospas
Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-(9CI)
beta-(4-Chlorophenyl)gaba
beta-(Aminomethyl)-4-chlorobenzenepropanoate
beta-(Aminomethyl)-4-chlorobenzenepropanoic acid
beta-(Aminomethyl)-P-chlorohydrocinnamate
beta-(Aminomethyl)-p-chlorohydrocinnamic acid
beta-(Aminomethyl)-P-chlorohydrocinnamic acid
beta-(P-Chlorophenyl)-gamma-aminobutyrate
beta-(p-Chlorophenyl)-gamma-aminobutyric acid
beta-(P-Chlorophenyl)-gamma-aminobutyric acid
Biomol-NT_000251
BPBio1_000012
BPBio1_000750
BRD-A84174873-001-05-2
BRN 2104494
BSPBio_000010
BSPBio_001880
C 34647Ba
C10H12ClNO2
CCRIS 3722
CHEBI:2972
CHEMBL701
Chlorophenyl gaba
Chlorophenyl GABA
Ciba 34,647-Ba
Ciba geigy brand OF baclofen
Ciba Geigy Brand of Baclofen
CIBA34,647ba
|
CIBA-34,647-ba
CIBA34,647BA
CIBA-34,647-BA
Ciba-geigy brand OF baclofen
Ciba-Geigy Brand of Baclofen
CID2284
Clofen
D001418
D00241
DB00181
DivK1c_000001
DL-4-amino-3-P-Chlorophenylbutanoate
DL-4-amino-3-P-Chlorophenylbutanoic acid
DL-4-Amino-3-p-chlorophenylbutanoic acid
DL-Baclofen
EINECS 214-486-9
EU-0100163
GABA, chlorophenyl
GABA, Chlorophenyl
Gabalon
g-amino-b-(P-Chlorophenyl)butyrate
g-amino-b-(P-Chlorophenyl)butyric acid
gamma-amino-beta-(P-Chlorophenyl)butyrate
gamma-amino-beta-(P-Chlorophenyl)butyric acid
gamma-Amino-beta-(p-chlorophenyl)butyric acid
Gen baclofen
Gen Baclofen
Gen-baclofen
GenBaclofen
Gen-Baclofen
Genpharm
HMS1568A12
HMS1920E21
HMS2091M03
HMS500A03
I01-1934
IDI1_000001
Irex brand OF baclofen
Irex Brand of Baclofen
Isis brand OF baclofen
Isis Brand of Baclofen
KBio1_000001
KBio2_000466
KBio2_003034
KBio2_005602
KBio3_001380
KBioGR_000650
KBioSS_000466
Kemstro
Kemstro (TN)
L000002
Lebic
Lioresal
Liorésal
Lioresal (TN)
Lioresal Intrathecal
Lopac0_000163
LS-77134
Medtronic brand OF baclofen
Medtronic Brand of Baclofen
MLS000028480
MolPort-002-051-370
NCGC00015156-05
NCGC00015156-12
NCGC00023843-03
NCGC00024579-03
NCGC00024579-04
NCGC00024579-05
NCGC00024579-06
NINDS_000001
Novartis brand OF baclofen
Novartis Brand of Baclofen
NSC329137
Nu baclo
Nu Baclo
Nu pharm brand OF baclofen
Nu Pharm Brand of Baclofen
Nu-baclo
NuBaclo
Nu-Baclo
Nu-Baclofen
Nu-pharm brand OF baclofen
Nu-Pharm Brand of Baclofen
Oprea1_440627
PCP-GABA
Pharmascience brand OF baclofen
Pharmascience Brand of Baclofen
PMS Baclofen
Pms-Baclofen
PMSBaclofen
PMS-Baclofen
Prestwick_85
Prestwick0_000085
Prestwick1_000085
Prestwick2_000085
Prestwick3_000085
SMP1_000036
SMR000058294
SPBio_000044
SPBio_001949
Spectrum_000066
SPECTRUM1500135
Spectrum2_000092
Spectrum3_000310
Spectrum4_000245
Spectrum5_000852
STK535284
STOCK2S-30552
UNII-H789N3FKE8
UPCMLD-DP142
UPCMLD-DP142:001
β-(4-chlorophenyl)gaba
β-(aminomethyl)-4-chlorobenzenepropanoate
β-(aminomethyl)-4-chlorobenzenepropanoic acid
β-(aminomethyl)-P-chlorohydrocinnamate
β-(aminomethyl)-P-chlorohydrocinnamic acid
β-(P-chlorophenyl)-γ-aminobutyrate
β-(P-chlorophenyl)-γ-aminobutyric acid
γ-amino-β-(P-chlorophenyl)butyrate
γ-amino-β-(P-chlorophenyl)butyric acid
|
|
17 |
|
Vitamin C |
Approved, Nutraceutical |
Phase 2, Phase 3 |
|
50-81-7 |
5785 54670067 |
Synonyms:
(+)-Ascorbate
(+)-Ascorbic acid
(+)-Sodium L-ascorbate
(2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one
(2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one
(5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one
129940-97-2
134-03-2 (monosodium salt)
14536-17-5
154170-90-8
2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one
255564_SIAL
259133-78-3
30208-61-8
33034_RIEDEL
33034_SIAL
3-keto-L-Gulofuranolactone
3-Keto-L-gulofuranolactone
3-oxo-L-Gulofuranolactone
3-Oxo-L-gulofuranolactone
3-Oxo-L-gulofuranolactone (enol form)
47863_SUPELCO
47A605F0-4187-47A8-B0CE-F9E7DA1B0076
50-81-7
50976-75-5
56172-55-5
56533-05-2
57304-74-2
57606-40-3
623158-95-2
6730-29-6
882690-91-7
884381-69-5
885512-24-3
88845-26-5
89924-69-6
95209_FLUKA
95209_SIGMA
95210_FLUKA
95210_SIAL
95212_FLUKA
A0278_SIGMA
A0537
A2174_SIGMA
A2218_SIGMA
A2343_SIGMA
A4403_SIGMA
A4544_SIGMA
A5960_SIGMA
A7506_SIGMA
A92902_ALDRICH
A92902_SIAL
AA
AB00376923
AB1002440
AC1L1L4T
AC1Q77S6
Acid Ascorbic
Acid, ascorbic
Acid, L-ascorbic
acide ascorbique
Acide ascorbique
Acide ascorbique [INN-French]
acido Ascorbico
Acido ascorbico
ácido ascórbico
Acido ascorbico [INN-Spanish]
Acidum ascorbicum
Acidum ascorbicum [INN-Latin]
acidum ascorbinicum
Acidum ascorbinicum
Adenex
Allercorb
Ambap36431-82-0
antiscorbic vita min
Antiscorbic vitamin
Antiscorbic Vitamin
Antiscorbutic factor
Antiscorbutic vitamin
Antiscorbutic Vitamin
AR-1J3435
arco-Cee
Arco-cee
Arco-Cee
Ascoltin
Ascoltin (TN)
Ascorb
ascor-b.i.d
Ascor-b.i.d.
Ascor-B.I.D.
Ascorbajen
ascorbate
Ascorbate
Ascorbate, ferrous
Ascorbate, magnesium
Ascorbate, sodium
ascorbic acid
Ascorbic acid
Ascorbic Acid
Ascorbic acid (JP15/USP/INN)
Ascorbic acid [BAN:INN:JAN]
Ascorbic acid [INN:BAN:JAN]
Ascorbic acid, monosodium salt
Ascorbic Acid, Monosodium Salt
Ascorbicab
Ascorbicap
Ascorbicap (TN)
Ascorbicin
Ascorbin
Ascorbinsaeure
Ascorbinsäure
Ascorbutina
Ascorbyl radical
Ascorin
Ascorteal
Ascorvit
bmse000182
BPBio1_000363
BSPBio_000329
C00072
C6H8O6
Cantan
Cantaxin
Caswell No. 061B
Catavin C
CCRIS 57
Ce lent
Ce Lent
Cebicure
Cebid
Cebion
Cebione
Cecon
cee-caps td
Cee-caps TD
Cee-Caps Td
Cee-Caps TD
Cee-vite
Cee-Vite
Cegiolan
Ceglion
Ceklin
Celaskon
Celin
Cell C
Cemagyl
Ce-mi-lin
Ce-Mi-Lin
Cemill
Cenetone
Cenolate
Cereon
Cergona
Cescorbat
Cetamid
Cetane
Cetane-caps TC
Cetane-Caps Tc
Cetane-Caps TC
Cetane-caps TD
Cetane-Caps Td
Cetane-Caps TD
Cetebe
Cetemican
Cevalin
|
Cevatine
Cevex
cevibid
Cevi-bid
Cevi-Bid
Cevimin
Ce-vi-sol
CE-VI-Sol
Cevital
Cevitamate
Cevitamic acid
Cevitamic Acid
Cevitamin
Cevitan
Cevitex
Cewin
CHEBI:29073
CHEMBL196
Chewcee
Ciamin
CID5785
Cipca
Citriscorb
Citrovit
C-Level
C-Long
Colascor
component of Cortalex
component of E and C-Level
component of Endoglobin Forte
component of Ferancee
Concemin
Cortalex
C-Quin
C-Span
C-Vimin
D00018
Davitamon C
DB00126
Di-L-ascorbate, magnesium
Dora-C-500
Duoscorb
e 300
e300
e-300
EINECS 200-066-2
FEMA No. 2109
Ferancee
Ferrous ascorbate
gamma-Lactone L-threo-hex-2-enonate
gamma-Lactone L-threo-hex-2-enonic acid
Hicee
HiCee
HSDB 818
Hybrin
ido-C
IDO-C
Iron(II) ascorbate
Iron-ascorbic acid complexes
Juvamine
Kangbingfeng
Kyselina askorbova
Kyselina Askorbova
Kyselina askorbova [Czech]
L Ascorbic acid
L(+)-Ascorbate
L-(+)-Ascorbate
L-(+)-ascorbic acid
L(+)-Ascorbic acid
L-(+)-Ascorbic acid
L-(+)-Ascorbic Acid
L-3-ketothreohexuronic acid
L-3-Ketothreohexuronic acid lactone
Laroscorbine
L-ascorbate
L-Ascorbate
l-ascorbic acid
L-Ascorbic acid
L-Ascorbic Acid
L-Ascorbic acid, free radical form
Lemascorb
Liqui-cee
Liqui-Cee
L-Lyxoascorbate
L-Lyxoascorbic acid
L-Lyxoascorbic Acid
LS-145
L-threo-ascorbic acid
L-threo-Ascorbic acid
L-Threoascorbic acid
l-threo-hex-1-eofuranos-3-ulose
L-threo-Hex-2-enonic acid, gamma-lactone
L-threo-hex-2-enono-1,4-lactone
L-Xyloascorbate
L-Xyloascorbic acid
L-Xyloascorbic Acid
Magnesium ascorbate
Magnesium ascorbicum
Magnesium Ascorbicum
Magnesium di L ascorbate
Magnesium di-L-ascorbate
Magnorbin
Meri-c
Meri-C
MLS002153776
MolPort-001-792-501
Monodehydroascorbic acid
Natrascorb
Natrascorb injectable
NCGC00091517-01
NCGC00091517-02
NCGC00164357-01
nchembio.174-comp5
nchembio.89-comp1
nchembio.92-comp2
nchembio821-comp9
NCI-C54808
NSC 33832
Oral Vitamin C
Planavit C
Prestwick3_000325
Proscorbin
Redoxon
Ribena
Ronotec 100
Rontex 100
roscorbi c
Roscorbic
Rovimix C
Scorbacid
Scorbu C
Scorbu-C
Secorbate
Semidehydroascorbate
SMR001233160
Sodascorbate
Sodium ascorbate
Sodium Ascorbate (Ascorbic Acid)
Stuartinic
Suncoat VC 40
Sunkist
Testascorbic
Tolfrinic
UNII-PQ6CK8PD0R
VASC
Vicelat
Vicin
Vicomin C
Viforcit
Viscorin
Viscorin 100m
Vitace
Vitacee
Vitacimin
Vitacin
vitamin C
Vitamin C
Vitamin- C
Vitamin-?C
Vitamina C
Vitamisin
Vitascorbol
W210901_ALDRICH
Xitix
|
|
18 |
|
carnitine |
|
Phase 2, Phase 3 |
|
|
|
19 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
20 |
|
Hematinics |
|
Phase 2, Phase 3 |
|
|
|
21 |
|
Neuroprotective Agents |
|
Phase 2, Phase 3 |
|
|
|
22 |
|
Epoetin alfa |
|
Phase 2, Phase 3 |
|
113427-24-0 |
|
23 |
|
Mexiletine |
Approved, Investigational |
Phase 2 |
|
31828-71-4 |
4178 |
Synonyms:
(+-)-1-(2,6-dimethylphenoxy)propan-2-amine
(+-)-1-(2,6-Dimethylphenoxy)propan-2-amine
(±)-1-(2,6-dimethylphenoxy)propan-2-amine
(2Rs)-1-(2,6-Dimethylphenoxy)-2-aminopropane
(2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane
1-(2',6'-dimethylphenoxy)-2-aminopropane
1-(2',6'-Dimethylphenoxy)-2-aminopropane
1-(2,6-dimethylphenoxy)-2-propanamine
1-(2,6-Dimethylphenoxy)-2-propanamine
1-(2,6-dimethylphenoxy)propan-2-amine
1-methyl-2-(2,6-xylyloxy)ethanamine
1-Methyl-2-(2,6-xylyloxy)ethanamine
1-Methyl-2-(2,6-xylyloxy)ethylamine
2-(2-aminopropoxy)-1,3-dimethylbenzene
2-(2-Aminopropoxy)-1,3-DiMethyl-Benzene Hydrochloride
31828-71-4
5370-01-4 (hydrochloride)
AB00053683
AC1L1HL7
AC1Q2BC5
AC1Q2BC6
Boehringer ingelheim brand OF mexiletine hydrochloride
BPBio1_000026
BRD-A64092382-003-04-3
BRN 2092205
BSPBio_000022
BSPBio_002254
C07220
CHEBI:115958
CHEBI:6916
CHEMBL558
CID4178
D08215
DB00379
DivK1c_000834
EINECS 250-825-7
I01-6374
IDI1_000834
KBio1_000834
KBio2_002082
KBio2_004650
KBio2_007218
|
KBio3_001474
KBioGR_001270
KBioSS_002082
KO1173
KO-1173
KOE-1173
Lopac0_000784
LS-68257
Mexiletene
Mexiletina
Mexiletina [INN-Spanish]
Mexiletine
Mexilétine
Mexiletine (INN)
Mexiletine [INN:BAN]
Mexiletine HCL
Mexiletine hydrochloride
Mexiletinum
Mexiletinum [INN-Latin]
Mexilitine
Mexitil
Mexitil PL
Mexityl
MolPort-001-790-944
NCGC00015659-04
NCGC00162253-01
NCGC00162253-02
NINDS_000834
novo Mexiletine
novo-Mexiletine
Novopharm brand OF mexiletine hydrochloride
Prestwick0_000241
Prestwick1_000241
Prestwick2_000241
Prestwick3_000241
SBB070242
SPBio_002241
Spectrum_001602
Spectrum3_000727
Spectrum4_000795
Spectrum5_001279
UNII-1U511HHV4Z
|
|
24 |
|
Coenzyme Q10 |
Approved, Investigational, Nutraceutical |
Phase 1, Phase 2 |
|
303-98-0 |
5281915 |
Synonyms:
(all-e)-2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
(all-e)-2,3-Dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-2,5-cyclohexadiene-1,4-dione
2-((all-e)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-P-benzoquinone
2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-P-benzoquinone
2,3-Dimethoxy-5-methyl-6-decaprenylbenzoquinone
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl- 2,5-cyclohexadiene-1,4-dione
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methyl-1,4-benzoquinone
4-Ethyl-5-fluoropyrimidine
Adelir
all-trans-Ubiquinone
Aqua Q 10l10
Aqua Q10
bio-Quinon
bio-Quinone Q10
Coenzyme Q10
Coenzyme Q-10
CO-Enzyme Q10
Coenzyme Q10, (Z,Z,Z,Z,Z,Z,e,e,e)-isomer
Coenzyme Q10, ion (1-), (all-e)-isomer
CoQ
CoQ 10
CoQ10
Ensorb
Kaneka Q10
|
Kudesan
Li-Q-sorb
Liquid-Q
Neuquinon
Neuquinone
PureSorb Q 40
Q
Q 10AA
Q 199
Q10
Q-Gel
Q-Gel 100
Q-Ter
Ubidecarenone
Ubiquinone
Ubiquinone 10
Ubiquinone 50
Ubiquinone Q10
UBIQUINONE-10
Ubisemiquinone
Ubisemiquinone radical
Unbiquinone
Unispheres Q 10
|
|
25 |
|
Ubiquinone |
|
Phase 1, Phase 2 |
|
|
|
26 |
|
Ulipristal acetate |
|
Phase 2 |
|
126784-99-4 |
|
27 |
|
Analgesics |
|
|
|
|
|
28 |
|
Insulin, Globin Zinc |
|
|
|
|
|
29 |
|
Hemostatics |
|
|
|
|
|
30 |
|
insulin |
|
|
|
|
|
31 |
|
Immunologic Factors |
|
|
|
|
|
32 |
|
Immunosuppressive Agents |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 61)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Association of Alpha Lipoic Acid to the Median Nerve Decompression in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. |
Completed |
NCT01895621 |
Phase 4 |
|
2 |
Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain |
Withdrawn |
NCT02748395 |
Phase 4 |
Triamcinolone;Lidocaine |
3 |
A Multicenter Study to Evaluate the Effects on Charcot−Marie−Tooth Neuropathy Type 1A of a Composite Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program. |
Unknown status |
NCT01289704 |
Phase 2, Phase 3 |
|
4 |
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months |
Completed |
NCT02579759 |
Phase 3 |
PXT3003 dose 1;PXT3003 dose 2;placebo |
5 |
A Randomized, Placebo-controlled, Double Masked 120 Subject "Futility Design" Clinical Trial of Ascorbic Acid Treatment of Charcot Marie Tooth Disease Type 1A. |
Completed |
NCT00484510 |
Phase 2, Phase 3 |
Ascorbic acid (Vitamin C);placebo |
6 |
Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome; a Randomized Control Trial. |
Completed |
NCT02141035 |
Phase 2, Phase 3 |
Acetyl-l-carnitine;placebo |
7 |
International, Multi-center, Open Label, 9-month Follow-up Extension Study Assessing the Long-term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A |
Active, not recruiting |
NCT03023540 |
Phase 3 |
PXT3003 |
8 |
Recombinant Human Erythropoietin (r-HuEPO) in the Prevention of Neurologic Sequelae From Malignant Spinal Cord Compression: a Multi-Center, Placebo-Controlled, Phase 2 Randomized Study |
Terminated |
NCT00220675 |
Phase 2, Phase 3 |
Erythropoietin infusion |
9 |
SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study |
Unknown status |
NCT02967679 |
Phase 1, Phase 2 |
MD1003 |
10 |
The Influence of Pronator Teres Release in the Treatment of Median Nerve Compression Neuropathy: A Randomized Prospective Study |
Unknown status |
NCT01562860 |
Phase 2 |
|
11 |
Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease |
Completed |
NCT02561702 |
Phase 2 |
Mexiletine |
12 |
A Phase II, Randomized, Placebo-controlled Trial of the Safety, Efficacy, Pharmacodynamics and Pharmacokinetics of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A. |
Completed |
NCT01401257 |
Phase 2 |
PXT3003 Low dose;PXT3003 Intermediate Dose;PXT3003 High Dose |
13 |
Effects of Coenzyme Q10 (CoQ10) on Subjects With Charcot-Marie-Tooth Disease (CMT):A Double Blind, Randomized, Controlled Trial With an Open Label Follow-up Study |
Completed |
NCT00541164 |
Phase 1, Phase 2 |
Coenzyme Q10 |
14 |
Neuropathy Along the Median Nerve: Etiology of Symptoms Associated With the Carpal Tunnel Syndrome, a Preliminary Study |
Completed |
NCT00634738 |
Phase 1, Phase 2 |
|
15 |
Phase 2 Study of Ascorbic Acid Treatment in Charcot-Marie-Tooth Type 1A |
Completed |
NCT00271635 |
Phase 2 |
Placebo;ascorbic acid |
16 |
Phase I/IIa Trial Evaluating scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Neuropathy Type 1A (CMT1A) |
Not yet recruiting |
NCT03520751 |
Phase 1, Phase 2 |
scAAV1.tMCK.NTF3 |
17 |
A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Charcot-Marie-Tooth Disease |
Terminated |
NCT03254199 |
Phase 2 |
FLX-787-ODT (orally disintegrating tablet);Placebo ODT |
18 |
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X |
Terminated |
NCT03124459 |
Phase 2 |
ACE-083;Placebo |
19 |
LONG-TERM EFFECTS TOLERANCE AND THE Ulipristal Acetate IN DISEASE Charcot-MARIE-TOOTH TYPE OF 1A |
Terminated |
NCT02600286 |
Phase 2 |
EllaOne;EllaOne placebo |
20 |
An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) Previously Enrolled in Study A083-02 and in Patients With Charcot-Marie Tooth (CMT) Disease Types 1 and X Previously Enrolled in Study A083-03 |
Terminated |
NCT03943290 |
Phase 2 |
ACE-083 |
21 |
Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers |
Unknown status |
NCT02596191 |
|
|
22 |
Development of the Charcot-Marie-Tooth Disease Infant Scale (CMTInfS) for Infants With CMT |
Unknown status |
NCT02979145 |
|
|
23 |
Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies |
Unknown status |
NCT03397303 |
|
|
24 |
Evaluation of the Analgesic Efficiency of the Transcutaneous Neurostimulation in the Charcot Syndrome Marie Tooth on the Pains of Lower Limbs |
Unknown status |
NCT01918826 |
|
|
25 |
Muscle Oxygenation Modification During Effort in 4 Groups of Neuromuscular Diseases Compared to Healthy Controls, and Mitochondrial Function and Phenotype Assessment |
Unknown status |
NCT02789059 |
|
|
26 |
Clinical and Genetic Features of Familial Neuropathy |
Completed |
NCT00149045 |
|
|
27 |
Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A |
Completed |
NCT01750710 |
|
|
28 |
Development and Validation of a Disability Severity Index for Charcot Marie Tooth Disease |
Completed |
NCT01455623 |
|
|
29 |
Survey of Current Management of Orthopaedic Complications in Charcot Marie Tooth Disease Patients |
Completed |
NCT02001038 |
|
|
30 |
Posterior Interosseous Nerve Pathology May Provide Novel Insights Into Both Predisposition and Potential Vascular Basis for the Development of Carpal Tunnel Syndrome in Diabetic Patients. |
Completed |
NCT00856011 |
|
|
31 |
Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS) |
Completed |
NCT02194010 |
|
|
32 |
An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients |
Completed |
NCT02429947 |
|
|
33 |
Clinical Outcomes of Surgical Release Among Diabetic Patients With Carpal Tunnel Syndrome. A Prospective Study With Matched Controls |
Completed |
NCT00775333 |
|
|
34 |
MRI of the Brachial Plexus and Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Assessment of DTI-derived Measurements at 3.0-T |
Completed |
NCT03460951 |
|
|
35 |
The Management of Abdominal Cutaneous Nerve Entrapment Syndrome |
Completed |
NCT03574727 |
|
|
36 |
Nociceptive Processing in Acute Cutaneous Nerve Entrapment Syndrome: a Quantitative Sensory Testing Analysis. |
Completed |
NCT01920880 |
|
|
37 |
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance |
Completed |
NCT02011204 |
|
|
38 |
Suprascapular Neuropathy in the Setting of Rotator Cuff Tears; Results of Arthroscopic Treatment |
Completed |
NCT02318381 |
|
|
39 |
Efficacy of Keyhole Approach to Carpal Tunnel Syndrome Under Ambulatory |
Completed |
NCT03062722 |
|
|
40 |
Patient Reported Outcomes Measures (PROM) in Carpal Tunnel Therapies in Patients With Inherited Neuropathies |
Completed |
NCT02788734 |
|
|
41 |
A Prospective Non-Randomized Unblinded Study Evaluating Treatment of Forefoot Pain Related to Nerve Entrapment Using the Cryo-Touch III Device |
Completed |
NCT01753778 |
|
|
42 |
A Randomized Double Blind Longitudinal Study to Determine Motor Unit Number Index Variability in CMT1A Patients Undergoing a Home Ankle Strengthening Program Versus Standard of Care |
Completed |
NCT03715283 |
|
|
43 |
BALTiC Study: A Feasibility Analysis of Home Based BALance Training in People With Charcot-Marie-Tooth Disease |
Completed |
NCT02982343 |
|
|
44 |
Accuracy of Ultrasonography and Electromyography in the Diagnosis of Carpal Tunnel Syndrome |
Completed |
NCT02553811 |
|
|
45 |
A Registered Observational Cohort Study of Charcot-Marie-Tooth Disease |
Recruiting |
NCT04010188 |
|
|
46 |
Genetics of Charcot Marie Tooth Disease (CMT) - Modifiers of CMT1A, New Causes of CMT |
Recruiting |
NCT01193088 |
|
|
47 |
The Impact of Charcot-Marie-Tooth Disease in the Real World |
Recruiting |
NCT03782883 |
|
|
48 |
Development and Validation of CMT Pediatric Scale for Children With Charcot Marie Tooth |
Recruiting |
NCT01203085 |
|
|
49 |
The Feasibility and Effect of Ankle Foot Orthoses and Underfoot Vibration on the Postural Stability of People With Inherited Neuropathy |
Recruiting |
NCT03278093 |
|
|
50 |
A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J) |
Recruiting |
NCT03810508 |
|
|
|